Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RS1 AAV Vector

Gene therapy

VVegaVect, Inc.

RS1 AAV Vector is one of 2 biologic programs targeting Retinoschisis. It is currently in development.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

RetinoschisisActive, not recruiting

RetinoschisisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Retinoschisis

#DrugCompanyPhaseTrials

Diamox

RS1 AAV Vector

VVegaVect, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Retinoschisis1 trial

Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis

Completed·VVegaVect, Inc.·Phase 1/2·NCT02317887·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RS1 AAV Vector. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RS1 AAV Vector compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RS1 AAV Vector. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — VegaVect, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Company: VVegaVect, Inc.

Related News